Validation of the Candida albicans delayed-type hypersensitivity (DTH) model in the female B6C3F1 mouse for use in immunotoxicological investigations

Journal of Immunotoxicology

Volumn 9, Issue 2, 2012, Pages 141-147

  White, Kimber L ^a   McLoughlin, Colleen E ^a,b   Auttachoat, Wimolnut ^a   Smith, Matthew J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Virginia Commonwealth University   (United States)

Author keywords

Azathioprine; Candida albicans; Cell mediated immunity; Cyclophosphamide; Cyclosporin A; Delayed type hypersensitivity (DTH) models; Dexamethasone; Immunotoxicity

Indexed keywords

AZATHIOPRINE; BENZO[E]PYRENE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; EX VIVO STUDY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; IN VIVO STUDY; JAUNDICE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN DISCOLORATION; WEIGHT REDUCTION;

CANDIDA ALBICANS; OVIS ARIES;

EID: 84860768687     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2011.636768     Document Type: Article

References (24)

1. Black C. A. 1999. Delayed type hypersensitivity: Current theories with an historic perspective. Dermatol. Online J. 5:7.
2. Borel J. F., Feurer C., Gubler H. U., and Stahelin H. 1976. Biological effects of cyclosporin A: A new anti-lymphocytic agent. Agents Actions 6:468-475.
3. Borel J. F., Feurer C., Magnee C., and Stahelin H. 1977. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32:1017-1025.
4. Burns-Naas L. A., Hastings K. L., Ladics G. S., Makris S. L., Parker G. A., and Holsapple M. P. 2008. What's so special about the developing immune system? Int. J. Toxicol.27:223-254.
5. Exon J. H., Bussiere J. L., and Mather G. G. 1990. Immunotoxicity testing in the rat: An improved multiple assay model. Int. J. Immunopharmacol. 12:699-701.
6. Henningsen G. M., Koller L. D., Exon J. H., Talcott P. A., and Osborne C. A. 1984. A sensitive delayed-Type hypersensitivity model in the rat for assessing in vivo cell-mediated immunity. J. Immunol. Meth. 70:153-165.
7. Holsapple M. P. 2002. Developmental immunotoxicology and risk assessment: A workshop summary. Hum. Exp. Toxicol. 21:473-478.
8. Holsapple M. P., Burns-Naas L. A., Hastings K. L., Ladics G. S., Lavin A. L., Makris S. L., Yang Y., and Luster M. I. 2005. A proposed testing framework for developmental immunotoxicology (DIT). Toxicol. Sci. 83:18-24.
9. Hurtrel B., Hurtrel M., and Lagrange P. H. 1984. Time course and histological differences between sheep red blood cells and tuberculin DTH reactions in mice. Ann. Immunol. (Paris) 135C:219-230.
10. Jerne N. K., Nordin A. A., and Henry C. 1963. The agar plaque technique for recognizing antibody-producing cells. In: Cell-Bound Antibodies. (Amos B., and Koprowski H., Eds.), Philadelphia, PA: Wistar Institute Press, 109-125.
11. Kaufmann S. H., and Schaible U. E. 2005. 100th Anniversary of Robert Koch's Nobel Prize for the discovery of the tubercle bacillus. Trends Microbiol. 13:469-475.
12. Kharazmi A., Svenson M., Nielsen H., and Birgens H. S. 1985. Effect of cyclosporin A on human neutrophil and monocyte function. Scand. J. Immunol. 21:585-591.
13. Lagrange P. H., and Mackaness G. B. 1975. A stable form of delayedtype hypersensitivity. J. Exp. Med. 141:82-96.
14. Lebrec H., Blot C., Pequet S., Roger R., Bohuon C., and Pallardy M. 1994. Immunotoxicological investigation using pharmaceutical drugs: In vivo evaluation of immune effects. Fundam. Appl. Toxicol. 23:159-168.
15. Luster M. I., Munson A. E., Thomas P., Holsapple M. P., Fenters J., White K. L., Lauer L. D., Germolec D. R., Rosenthal G. J., and Dean J. H. 1988. Development of a testing battery to assess chemicalinduced immunotoxicity: National Toxicology Program Guidelines for Immunotoxicity Evaluation in Mice. Fundam. Appl. Toxicol. 10:2-19.
16. Mackaness G. B., Lagrange P. H., Miller T. E., and Ishibashi T. 1974. Feedback inhibition of specifically sensitized lymphocytes. J. Exp. Med. 139:543-559.
17. Morikawa Y., Kuribayashi K., Yoshikawa F., Fujita K., Mizushima A., and Kakudo K. 1991. The role of antibodies in the regulation of delayed-Type hypersensitivity. Immunology 74:146-152.
18. Nghiem D. X., Walterscheid J. P., Kazimi N., and Ullrich S. E. 2002. Ultraviolet radiation-induced immunosuppression of delayedtype hypersensitivity in mice. Methods 28:25-33.
19. Plitnick L. M., and Herzyk D. J. 2010. The T-dependent antibody response to keyhole limpet hemocyanin in rodents. Methods Mol. Biol. 598:159-171.
20. Smith M. J., and White K. L. 2010. Establishment and comparison of delayed-Type hypersensitivity models in the B6C3F1 mouse. J. Immunotoxicol. 7:308-317.
21. Temple L., Kawabata T. T., Munson A. E., and White K. L. Jr. 1993. Comparison of ELISA and plaque-forming cell assays for measuring the humoral immune response to SRBC in rats and mice treated with benzo[a]pyrene or cyclophosphamide. Fundam. Appl. Toxicol. 21:412-419.
22. Vos J. G. 1980. Immunotoxicity assessment: Screening and function studies. Arch. Toxicol. Suppl. 4:95-108.
23. White K. L., Musgrove D. L., and Brown R. D. 2010. The Sheep Erythrocyte T-Dependent Antibody Response (TDAR). Methods Mol. Biol. 598:173-184.
24. Whittingham S., Feery B., and Mackay I. R. 1982. Use of tetanus toxoid for testing cell-mediated immunity. Aust. NZ J. Med. 12:511-514.